For the treatment of moderate to severe hidradenitis suppurativa (HS) in patients 12 years of age and older

SAME HUMIRA YOU KNOW AND TRUST IN AN 80 MG EVERY-OTHER-WEEK (EOW) MAINTENANCE DOSE

After 2 initiation doses, 80 mg EOW offers appropriate patients (≥12 years, ≥132 lbs) dosing with anticipated comparable efficacy and safety predicted through PK/PD modeling and simulation.1

After 2 initiation doses, 80 mg EOW offers appropriate patients (≥12 years, ≥132 lbs) dosing with anticipated comparable efficacy and safety predicted through PK/PD modeling and simulation.1

HALF THE INJECTIONS WITH 80 MG EOW MAINTENANCE DOSING1

In appropriate patients (≥12 years, ≥132 lbs) after 2 initiation doses compared to 40 mg weekly maintenance dosing

Half the injections compared to 40 mg weekly maintenance option after 2 initiation doses

Citrate-free formulation provides less pain immediately following injection2*

Anticipated comparable efficacy and safety predicted through PK/PD modeling and simulation based on 40 mg weekly

HUMIRA Citrate-free pen.

*Injection site pain immediately following injection as measured using a 0-10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.

dosing in HS1

HUMIRA Citrate-free is administered by subcutaneous injection. Weight-based dosing is only for adolescent patients.

Initial Dosing

Three single HUMIRA dosing pens for day 1 and day 15.

NDC: 0074-0124-03
(HS Adult Starter Pack: 3-count HUMIRA Pen 80 mg/0.8 mL)

Maintenance Dosing

Single HUMIRA dosing pen for day 29.

NDC: 0074-0124-02
(Pen Carton: 2-count HUMIRA Pen 80 mg/0.8 mL)

HUMIRA HS DOSING SCHEDULE FOR
ADULTS & ADOLESCENTS (≥12 YEARS, ≥132 LBS)

Female HS patient.
Every other week 80 mg maintenance dose for appropriate patients.

Also available in 40 mg weekly maintenance dosing
NDC: 0074-0554-02
(Pen Carton 2-count HUMIRA Pen 40 mg/0.4 mL)

NDC=National Drug Code;

PD=pharmacodynamic;

PK=pharmacokinetic.

 

 

The initial dose can be administered as two 80 mg injections in 1 day or as one 80 mg injection per day for 2 consecutive days.

Initial Dosing

Day 1 HUMIRA dosing pen, Day 8 HUMIRA dosing pen, and Day 22 HUMIRA dosing pen.

NDC: 0074-1539-03
(HS Adolescent Starter Pack: 1-count HUMIRA Pen 80 mg/0.8 mL + 2-count HUMIRA Pen 40 mg/0.4 mL)

Maintenance Dosing

Single HUMIRA dosing pen for day 36.

NDC: 0074-0554-02
(Pen Carton: 2-count HUMIRA Pen 40 mg/0.4 mL)

HUMIRA HS DOSING SCHEDULE FOR ADOLESCENTS (≥12 YEARS, 66 LBS to <132 LBS)

Smiling female HS patient.

Download the HUMIRA HS Dosing Flashcard

Get details on dosing information for your HS patients.

Dosing Considerations1

The first injection should be given under the supervision of a healthcare professional. A patient may self-inject HUMIRA after appropriate training and monitoring by a healthcare professional.

Instruct patients to rotate injection sites and not to inject into areas where the skin is tender, bruised, red, or hard.

In clinical trials, injection site reactions (erythema and/or itching, hemorrhage, pain, or swelling) were reported in 20% of HUMIRA-treated patients vs 14% of placebo-treated patients. Most reactions were mild and did not require discontinuation.

The most common adverse reactions in HUMIRA clinical trials (incidence >10%) were: infections (eg, upper respiratory, sinusitis), injection site reactions, headache, and rash.

No citrate buffers. Thinner needle (29 gauge vs 27 gauge). Less pain immediately following injection when compared with the HUMIRA 40 mg/0.8 mL presentation.2§‖

HUMIRA Citrate-free pen.

§HUMIRA Citrate-free is available to all indicated patients in the United States. HUMIRA Citrate-free features the same safety and efficacy profile of HUMIRA you've come to count on.1,2

Injection site pain immediately following injection as measured using a 0-10 cm Visual Analog Scale: HUMIRA 40 mg/0.4 mL vs HUMIRA 40 mg/0.8 mL.2